Literature DB >> 15249368

The phenotype of Leber congenital amaurosis in patients with AIPL1 mutations.

Sharola Dharmaraj1, Bart P Leroy, Melanie M Sohocki, Robert K Koenekoop, Isabelle Perrault, Khalid Anwar, Shagufta Khaliq, R Summathi Devi, David G Birch, Elaine De Pool, Natalio Izquierdo, Lionel Van Maldergem, Mohammad Ismail, Annette M Payne, Graham E Holder, Shomi S Bhattacharya, Alan C Bird, Josseline Kaplan, Irene H Maumenee.   

Abstract

OBJECTIVES: To describe the phenotype of Leber congenital amaurosis (LCA) in 26 probands with mutations in aryl hydrocarbon receptor interacting protein-like 1 protein (AIPL1) and compare it with phenotypes of other LCA-related genes. To describe the electroretinogram (ERG) in heterozygote carriers.
METHODS: Patients with AIPL1-related LCA were identified in a cohort of 303 patients with LCA by polymerase chain reaction single-strand confirmational polymorphism mutation screening and/or direct sequencing. Phenotypic characterization included clinical and ERG evaluation. Seven heterozygous carrier parents also underwent ERG testing.
RESULTS: Seventeen homozygotes and 9 compound heterozygotes were identified. The W278X mutation was most frequent (48% of alleles). Visual acuities ranged from light perception to 20/400. Variable retinal appearances, ranging from near normal to varying degrees of chorioretinal atrophy and intraretinal pigment migration, were noted. Atrophic and/or pigmentary macular changes were present in 16 (80%) of 20 probands. Keratoconus and cataracts were identified in 5 (26%) of 19 patients, all of whom were homozygotes. The ERG of a parent heterozygote carrier revealed significantly reduced rod function, while ERGs for 6 other carrier parents were normal.
CONCLUSIONS: The phenotype of LCA in patients with AIPL1 mutations is relatively severe, with a maculopathy in most patients and keratoconus and cataract in a large subset. Rod ERG abnormalities may be present in heterozygous carriers of AIPL1 mutations. CLINICAL RELEVANCE: Understanding and recognizing the phenotype of LCA may help in defining the course and severity of the disease. Identifying the gene defect is the first step in preparation for therapy since molecular diagnosis in LCA will mandate the choice of treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249368     DOI: 10.1001/archopht.122.7.1029

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  40 in total

Review 1.  Gene therapy for Leber congenital amaurosis: advances and future directions.

Authors:  Robert B Hufnagel; Zubair M Ahmed; Zélia M Corrêa; Robert A Sisk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-29       Impact factor: 3.117

2.  [Genetic and clinical heterogeneity in LCA patients. The end of uniformity].

Authors:  M N Preising; K Paunescu; C Friedburg; B Lorenz
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

3.  AIPL1, a protein associated with childhood blindness, interacts with alpha-subunit of rod phosphodiesterase (PDE6) and is essential for its proper assembly.

Authors:  Saravanan Kolandaivelu; Jing Huang; James B Hurley; Visvanathan Ramamurthy
Journal:  J Biol Chem       Date:  2009-09-16       Impact factor: 5.157

4.  Unique structural features of the AIPL1-FKBP domain that support prenyl lipid binding and underlie protein malfunction in blindness.

Authors:  Ravi P Yadav; Lokesh Gakhar; Liping Yu; Nikolai O Artemyev
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

5.  Interaction of the tetratricopeptide repeat domain of aryl hydrocarbon receptor-interacting protein-like 1 with the regulatory Pγ subunit of phosphodiesterase 6.

Authors:  Ravi P Yadav; Kimberly Boyd; Liping Yu; Nikolai O Artemyev
Journal:  J Biol Chem       Date:  2019-09-05       Impact factor: 5.157

Review 6.  Juvenile Macular Degenerations.

Authors:  Pablo Altschwager; Lucia Ambrosio; Emily A Swanson; Anne Moskowitz; Anne B Fulton
Journal:  Semin Pediatr Neurol       Date:  2017-05-23       Impact factor: 1.636

7.  Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.

Authors:  Mei Hong Tan; Alexander J Smith; Basil Pawlyk; Xiaoyun Xu; Xiaoqing Liu; James B Bainbridge; Mark Basche; Jenny McIntosh; Hoai Viet Tran; Amit Nathwani; Tiansen Li; Robin R Ali
Journal:  Hum Mol Genet       Date:  2009-03-19       Impact factor: 6.150

8.  Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis.

Authors:  Sirichai Pasadhika; Gerald A Fishman; Edwin M Stone; Martin Lindeman; Ruth Zelkha; Irma Lopez; Robert K Koenekoop; Mahnaz Shahidi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-03       Impact factor: 4.799

9.  A novel VSX1 mutation identified in an individual with keratoconus in India.

Authors:  Preeti Paliwal; Anuradha Singh; Radhika Tandon; Jeevan S Titiyal; Arundhati Sharma
Journal:  Mol Vis       Date:  2009-11-28       Impact factor: 2.367

10.  Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations.

Authors:  X Sun; B Pawlyk; X Xu; X Liu; O V Bulgakov; M Adamian; M A Sandberg; S C Khani; M-H Tan; A J Smith; R R Ali; T Li
Journal:  Gene Ther       Date:  2009-08-27       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.